Department of Medicine, University of South Carolina School of Medicine, Columbia.
Department of Pathology, University of Arizona College of Medicine, Arizona Cancer Center, Tucson.
Forty years after prostate-specific antigen (PSA) was identified and nearly 20 years after it became available for prostate-cancer screening, the U.S. Preventive Services Task Force (USPSTF) recently recommended against PSA-based screening.(1) In the interim, untold millions of men have been tested. Because PSA is not cancer-specific and because prostate cancer's aggressiveness varies widely, controversy and debate about PSA screening were predictable from the outset. Although we agree fully with the task force's analysis, there are three issues that the panel did not address but that are relevant to primary care clinicians, who initiate most PSA screening. (One of us is . . .
Written by:
Brett AS, Ablin RJ. Are you the author?
Reference: N Engl J Med. 2011 Oct 26. Epub ahead of print.
doi: 10.1056/NEJMp1112191
PubMed Abstract
PMID: 22029759
UroToday.com Prostate Cancer Section
